Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 49

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 49
---
574  $(5,011,891 ) $1,156,392  $(409,062 ) $6,665,013                          Impacts arising from application of Topic 326  -   -   -   (371,627 )  -   (371,627 )                         Balance as of January 1, 2023 (restated)  14,476,513  $10,929,574  $(5,011,891 ) $784,765  $(409,062 ) $6,293,386                          Round up shares  1,044,351   1,046   -   -   -   1,046                          Issuance of shares*  1,437,500   5,750,000   -   -   -   5,750,000                          Issuance of shares#  709,299   510,695   -   -   -   510,695                          Net loss for the year  -   -   -   (2,629,043 )  -   (2,629,043 )                         Foreign currency translation loss  -   -   -   -   (268,232 )  (268,232 )                         Balance as of December 31, 2023  17,667,663  $17,191,315  $(5,011,891 ) $(1,844,278 ) $(677,294 ) $9,657,852 

Share activity (number of shares or both number and amount of shares) has been adjusted for the periods shown to reflect the 12-for-1 reverse stock split effected on July 20, 2023, on a retroactive basis

* 1,437,500 shares of common stock were issued to the underwriter.

# 834,299 shares of common stock were issued to professional parties and board members

  Common stock                     Accumulated       Number of     Additionalpaid in   Accumulated  other comprehensive  Totalstockholders’   shares  Amount  capital  deficit